Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
Abstract Background Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, s...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-12-01
|
| Series: | BMC Ophthalmology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12886-018-0978-9 |
| _version_ | 1818562265125748736 |
|---|---|
| author | Patrick R. Merz Nina Röckel Seda Ballikaya Gerd U. Auffarth Ingo Schmack |
| author_facet | Patrick R. Merz Nina Röckel Seda Ballikaya Gerd U. Auffarth Ingo Schmack |
| author_sort | Patrick R. Merz |
| collection | DOAJ |
| description | Abstract Background Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endothelial growth factor (VEGF) antibodies. The aim of the study was to investigate potential cytotoxic effects of two anti-VEGF agents, ranibizumab (Lucentis®) and bevacizumab (Avastin®) on the human corneal endothelium. Methods Human donor corneas, not suitable for corneal transplantation, were organ-cultured in the presence of either ranibizumab (Lucentis®) or bevacizumab (Avastin®) at different concentrations (group 1: 250 μg / ml, group 2: 25 μg / ml, group 3: 2.5 μg / ml) for a period of up to 4 weeks. Microscopic imaging for endothelial cell counting, detection of morphologic alterations of the endothelium, and molecular biology testing (Enzyme-linked Immunosorbent Assay [ELISA]) for metabolic changes was performed. Results Background-corrected results showed neither a significant lactate dehydrogenase (LDH) change with increasing culturing time nor a significant difference between ranibizumab (Lucentis®) and bevacizumab (Avastin®) treatment. The endothelial cell density revealed also no statistically significant difference between the two treatment groups with ranibizumab (Lucentis®) and bevacizumab (Avastin®) at all concentrations tested in this study. Conclusions In this study, the anti-angiogenic agents ranibizumab (Lucentis®) and bevacizumab (Avastin®) demonstrated no cytotoxic effects on the corneal endothelium of human organ-cultured donor corneas over the limited study time period of 4 weeks. However, based on the study design (in-vitro) and the limited follow-up period, no conclusions on potential long-term effects can be drawn. |
| first_indexed | 2024-12-14T01:01:26Z |
| format | Article |
| id | doaj.art-2c9d05695b7046be889a52aff242c4df |
| institution | Directory Open Access Journal |
| issn | 1471-2415 |
| language | English |
| last_indexed | 2024-12-14T01:01:26Z |
| publishDate | 2018-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Ophthalmology |
| spelling | doaj.art-2c9d05695b7046be889a52aff242c4df2022-12-21T23:23:14ZengBMCBMC Ophthalmology1471-24152018-12-011811810.1186/s12886-018-0978-9Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cellsPatrick R. Merz0Nina Röckel1Seda Ballikaya2Gerd U. Auffarth3Ingo Schmack4Department of Ophthalmology, University of Heidelberg, Lions Eye BankDepartment of Ophthalmology, University of Heidelberg, Lions Eye BankDepartment of Ophthalmology, University of Heidelberg, Lions Eye BankDepartment of Ophthalmology, University of Heidelberg, Lions Eye BankDepartment of Ophthalmology, University of Heidelberg, Lions Eye BankAbstract Background Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endothelial growth factor (VEGF) antibodies. The aim of the study was to investigate potential cytotoxic effects of two anti-VEGF agents, ranibizumab (Lucentis®) and bevacizumab (Avastin®) on the human corneal endothelium. Methods Human donor corneas, not suitable for corneal transplantation, were organ-cultured in the presence of either ranibizumab (Lucentis®) or bevacizumab (Avastin®) at different concentrations (group 1: 250 μg / ml, group 2: 25 μg / ml, group 3: 2.5 μg / ml) for a period of up to 4 weeks. Microscopic imaging for endothelial cell counting, detection of morphologic alterations of the endothelium, and molecular biology testing (Enzyme-linked Immunosorbent Assay [ELISA]) for metabolic changes was performed. Results Background-corrected results showed neither a significant lactate dehydrogenase (LDH) change with increasing culturing time nor a significant difference between ranibizumab (Lucentis®) and bevacizumab (Avastin®) treatment. The endothelial cell density revealed also no statistically significant difference between the two treatment groups with ranibizumab (Lucentis®) and bevacizumab (Avastin®) at all concentrations tested in this study. Conclusions In this study, the anti-angiogenic agents ranibizumab (Lucentis®) and bevacizumab (Avastin®) demonstrated no cytotoxic effects on the corneal endothelium of human organ-cultured donor corneas over the limited study time period of 4 weeks. However, based on the study design (in-vitro) and the limited follow-up period, no conclusions on potential long-term effects can be drawn.http://link.springer.com/article/10.1186/s12886-018-0978-9Corneal neovascularizationCorneal endothelial cellsCorneal angiogenesisVascular endothelial growth factorRanibizumabBevacizumab |
| spellingShingle | Patrick R. Merz Nina Röckel Seda Ballikaya Gerd U. Auffarth Ingo Schmack Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells BMC Ophthalmology Corneal neovascularization Corneal endothelial cells Corneal angiogenesis Vascular endothelial growth factor Ranibizumab Bevacizumab |
| title | Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
| title_full | Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
| title_fullStr | Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
| title_full_unstemmed | Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
| title_short | Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
| title_sort | effects of ranibizumab lucentis r and bevacizumab avastin r on human corneal endothelial cells |
| topic | Corneal neovascularization Corneal endothelial cells Corneal angiogenesis Vascular endothelial growth factor Ranibizumab Bevacizumab |
| url | http://link.springer.com/article/10.1186/s12886-018-0978-9 |
| work_keys_str_mv | AT patrickrmerz effectsofranibizumablucentisandbevacizumabavastinonhumancornealendothelialcells AT ninarockel effectsofranibizumablucentisandbevacizumabavastinonhumancornealendothelialcells AT sedaballikaya effectsofranibizumablucentisandbevacizumabavastinonhumancornealendothelialcells AT gerduauffarth effectsofranibizumablucentisandbevacizumabavastinonhumancornealendothelialcells AT ingoschmack effectsofranibizumablucentisandbevacizumabavastinonhumancornealendothelialcells |